TY  - JOUR
AU  - Park, Keunchil
AU  - Haura, Eric B.
AU  - Leighl, Natasha B.
AU  - Mitchell, Paul
AU  - Shu, Catherine A.
AU  - Girard, Nicolas
AU  - Viteri, Santiago
AU  - Han, Ji-Youn
AU  - Kim, Sang-We
AU  - Lee, Chee Khoon
AU  - Sabari, Joshua K.
AU  - Spira, Alexander, I
AU  - Yang, Tsung-Ying
AU  - Kim, Dong-Wan
AU  - Lee, Ki Hyeong
AU  - Sanborn, Rachel E.
AU  - Trigo, Jose
AU  - Goto, Koichi
AU  - Lee, Jong-Seok
AU  - Yang, James Chih-Hsin
AU  - Govindan, Ramaswamy
AU  - Bauml, Joshua M.
AU  - Garrido, Pilar
AU  - Krebs, Matthew G.
AU  - Reckamp, Karen L.
AU  - Xie, John
AU  - Curtin, Joshua C.
AU  - Haddish-Berhane, Nahor
AU  - Roshak, Amy
AU  - Millington, Dawn
AU  - Lorenzini, Patricia
AU  - Thayu, Meena
AU  - Knoblauch, Roland E.
AU  - Cho, Byoung Chul
PY  - 2021
DO  - 10.1200/JCO.21.00662
SN  - 0732-183X
UR  - https://hdl.handle.net/10668/27015
T2  - Journal of clinical oncology
AB  - PURPOSE Non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody with...
LA  - en
PB  - Lippincott williams & wilkins
KW  - Growth-factor receptor
KW  - Bispecific antibody
KW  - Gene-mutations
KW  - Trial
KW  - Jnj-61186372
KW  - Gefitinib
KW  - Outcomes
KW  - Nsclc
KW  - Cmet
TI  - Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
TY  - research article
VL  - 39
ER  -